The growth for Vertex’s Journavax painkiller is just beginning to ramp up, given the potential size of the nonaddictive drug ...
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform ...
Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the most profitable biotech stocks to buy. H.C. Wainwright ...
Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.
Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.
Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...
Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
Leading Chinese solar manufacturer Trinasolar has signed a module supply agreement with Malaysian renewable energy developer ...
A former executive at Microsoft, McAfee and Cisco becomes the fourth CEO in Vertex's 47-year history.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback